Healthcare / Medical Instruments & SuppliesShenzhen
$11.84
+0.06 (+0.51%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 19%
FCF escenarios
weak_data · normalized FCF $382.1M · quality 51.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
38/100
D
Piotroski
6/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$9.1B
P/E
43.9x
↑EV/EBITDA
14.5x
↑ROE
2.5%
↑Gross Margin
29.3%
↓Debt/Equity
0.01
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-1.5%
FCF CAGR
—
FCF margin
8.8%
FCF / Net income
2.29x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $5.23B · net income $200.4M · FCF $459.6M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $5.23B | $5.23B | $5.01B | $5.64B | $5.47B |
| Net Income | $200.4M | $200.4M | $194.1M | $600.2M | $846.6M |
| EBITDA | $420.3M | $420.3M | $343.5M | $799.5M | $1.07B |
| EPS | 0.26 | 0.26 | 0.26 | 0.79 | 1.33 |
| Gross Margin | 29.3% | 29.3% | 29.2% | 35.1% | 39.0% |
| Operating Margin | 6.2% | 6.2% | 7.2% | 13.0% | 20.0% |
| Net Margin | 3.8% | 3.8% | 3.9% | 10.6% | 15.5% |
| Balance Sheet | |||||
| Debt/Equity | 0.01 | 0.01 | 0.00 | 0.00 | 0.00 |
| Current Ratio | 1.98 | 1.98 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $459.6M | $459.6M | $382.1M | $-1.02B | $-478.6M |
| Returns | |||||
| ROE | 2.5% | 2.5% | 2.5% | 7.6% | 11.4% |
| Valuation | |||||
| P/E | 43.85 | 43.85 | 47.65 | 21.84 | 19.64 |
| EV/EBITDA | 14.50 | 14.50 | 19.66 | 13.54 | 11.16 |
| P/B | 1.15 | 1.15 | 1.18 | 1.66 | 2.23 |
| Growth & Yield | |||||
| Revenue Growth | 4.4% | 4.4% | -11.2% | 3.1% | — |
| EPS Growth | 0.0% | 0.0% | -67.1% | -40.6% | — |
| Dividend Yield | 0.9% | 0.9% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
59.3%
EPS terminal req.
$1.05
Spread vs growth
-59.3%
5Y implied EPS CAGR
37.4%
EPS terminal req.
$1.27
Spread vs growth
-37.4%
10Y implied EPS CAGR
22.9%
EPS terminal req.
$2.05
Spread vs growth
-22.9%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-0.2%
Start / end P/E
46.1x → 45.5x
EPS bridge
0.26 → 0.26
Residual
+0.0%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.